Peptides DB
Research-centric peptide and protocol reference hub
Study 38 of 38Abaloparatide (Tymlos) literatureArchives of osteoporosis · Observational2026

Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study.

Approximately 30% of patients restart denosumab within one year after discontinuation, and half receive no further osteoporosis treatment, highlighting a gap in care.

Read at Archives of osteoporosisAdd to compare

Where it sits

this study against the rest of the abaloparatide (tymlos) corpus
9
Preclinical
13
Observational · this one
0
Open-label
3
Randomised
13
Reviews

Summary and findings

This study examined treatment patterns following denosumab discontinuation in adults aged ≥40 years. Within one year, approximately 30% of patients restarted denosumab, 50% had no subsequent osteoporosis treatment, and 16% initiated sequential osteoporosis therapy. The study utilized a Japanese claims database from April 2014 to March 2024.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →
29.6% delayed denosumab reinitiation within 1 year, n=37526.n=375262026

Abstract

The authors’ words, as Archives of osteoporosis supplied them

This descriptive epidemiological study suggests that sequential osteoporosis therapy after denosumab discontinuation is underutilized in real-world practice. Within 1 year after discontinuation, approximately 30% of patients restarted denosumab, approximately half had no subsequent osteoporosis treatment, and only 16% initiated sequential osteoporosis therapy.<h4>Purpose</h4>To describe real-world treatment patterns following denosumab discontinuation, including delayed reinitiation, no subsequent osteoporosis treatment, and sequential osteoporosis therapy.<h4>Methods</h4>This descriptive epidemiological study used a Japanese claims database (April 2014-March 2024). We included adults aged ≥40 years who newly initiated denosumab and discontinued it after ≥2 doses. Discontinuation was defined as the last administration before a gap of >240 days or final observed administration followed by ≥240 days without another administration. The primary outcomes within 1 year after discontinuation were delayed denosumab reinitiation, no subsequent osteoporosis treatment, and sequential osteoporosis therapy. We also described the type and timing of sequential therapy and estimated the 1-year cumulative incidence of fragility fractures.<h4>Results</h4>Among 37,526 eligible patients, the 1-year cumulative incidence of delayed denosumab reinitiation was 29.6%, the probability of no subsequent osteoporosis treatment was 50.9%, and the cumulative incidence of sequential osteoporosis therapy was 16.3%. Oral bisphosphonates were the most frequently used sequential therapy (26.7%), followed by romosozumab (22.2%), selective estrogen receptor modulators (21.3%), intravenous bisphosphonates (15.1%), teriparatide (14.6%), and abaloparatide (0.1%). Sequential therapy was most often initiated 180-209 days after discontinuation, particularly for romosozumab (45.7%), whereas selective estrogen receptor modulators were frequently initiated 0-29 days after discontinuation (39.8%). The 1-year cumulative incidence of fragility fractures was 5.4%.<h4>Conclusions</h4>Within 1 year after discontinuation, approximately 30% of patients restarted denosumab, half received no subsequent osteoporosis treatment, and one in six initiated sequential therapy. These findings suggest a substantial gap in the continuity of osteoporosis care.

Background

This study addresses the treatment patterns following the discontinuation of denosumab, a medication used for osteoporosis. Previous research has indicated that discontinuation of osteoporosis therapies can lead to gaps in treatment and increased fracture risk. Understanding these patterns is crucial for improving osteoporosis management and ensuring continuity of care.

Methods

This descriptive epidemiological study utilized a Japanese claims database covering April 2014 to March 2024. The population included adults aged ≥40 years who had initiated denosumab and discontinued it after receiving at least two doses. The primary outcomes assessed within one year after discontinuation included delayed reinitiation of denosumab, no subsequent osteoporosis treatment, and initiation of sequential osteoporosis therapy.

Results

The primary endpoint revealed that 29.6% of patients delayed reinitiating denosumab within one year, n=37526. Additionally, 50.9% of patients received no subsequent osteoporosis treatment, and only 16.3% initiated sequential therapy. The cumulative incidence of fragility fractures within one year was reported at 5.4%, n=37526.

Interpretation

The findings indicate a significant gap in osteoporosis treatment continuity, as a substantial proportion of patients either did not resume treatment or did not initiate sequential therapy after denosumab discontinuation. While the study provides important insights into treatment patterns, the small percentage of patients using abaloparatide (0.1%) suggests limited uptake in real-world settings. The observational nature of the study and reliance on claims data may introduce confounding factors that limit the ability to draw definitive conclusions about treatment effectiveness.

Key findings

  • 29.6% delayed denosumab reinitiation within 1 year, n=37526.
  • 50.9% had no subsequent osteoporosis treatment within 1 year, n=37526.
  • 16.3% initiated sequential osteoporosis therapy within 1 year, n=37526.
  • 1-year cumulative incidence of fragility fractures was 5.4%, n=37526.
  • Oral bisphosphonates were used by 26.7% for sequential therapy, n=37526.
  • Abaloparatide was used by 0.1% for sequential therapy, n=37526.

Limitations

  • Observational study design limits causal inferences.
  • Relies on claims data, which may not capture all treatment nuances.
  • Single-country data may not generalize to other populations.
  • No assessment of patient outcomes or satisfaction with treatment.

Elsewhere in the Abaloparatide (Tymlos) corpus

AParathyroid Hormone for Medication-Related Osteonecrosis of the Jaw: A Systematic Review and Meta-Analysis.Oral diseases · 2024 · n=278 · Odds ratio 5.81.reviewCBone anabolic agents repair alveolar bone damaged by diabetes in mice.International journal of oral science · 2026 · Not reported in abstract.AnimalABeyond antifracture efficacy: Osteoanabolic versus antiresorptive therapy for chronic pain after osteoporotic vertebral fractures. A systematic review and meta-analysis.Bone · 2026 · n=4029 · Not reported in abstract.reviewABone Anabolic Treatment in Patients With Chronic Kidney Disease: A Systematic Review.Basic & clinical pharmacology & toxicology · 2023 · n=66 · Not reported in abstract.reviewBReal-world comparison of abaloparatide and romosozumab: effects on bone mineral density and three-dimensional hip structure.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023 · n=102 · Significant increases in lumbar spine BMD at 12 months, P<0.001.HumanDAnti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map.Calcified tissue international · 2026 · Not reported in abstract.review